Related Experiment Videos
The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors
V Rusch1, J Mendelsohn, E Dmitrovsky
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. ruschv@mskcc.org
Abstract:
The epidermal growth factor receptor (EGFR) is detected on many non-haematopoietic tissues and is frequently overexpressed in human tumors. With its ligand, TGF-alpha, it forms a well-defined autocrine growth loop. Several clinical approaches, using EGFR as a therapeutic target, are being investigated, particularly monoclonal antibodies combined with chemotherapy, and pharmacological inhibition of downstream components of the EGFR signaling pathway.
Insights
Epidermal growth factor receptor (EGFR) is overexpressed in human tumors, forming an autocrine growth loop with TGF-alpha. Clinical strategies targeting EGFR, including antibodies and pathway inhibitors, are under investigation for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Epidermal Growth Factor Receptor (EGFR) is present in various non-hematopoietic tissues.
- EGFR is frequently overexpressed in human tumors, contributing to cancer progression.
- EGFR and its ligand TGF-alpha form a critical autocrine growth loop.
Purpose of the Study:
- To review the role of EGFR in human tumors.
- To discuss current and emerging clinical strategies targeting EGFR.
- To highlight therapeutic approaches focused on inhibiting EGFR signaling pathways.
Main Methods:
- Review of existing literature on EGFR.
- Analysis of clinical trial data for EGFR-targeted therapies.
- Examination of the molecular mechanisms of EGFR signaling.
Main Results:
- EGFR overexpression is a common feature in many human cancers.
- Targeting EGFR offers a promising therapeutic avenue.
- Monoclonal antibodies and small molecule inhibitors are key therapeutic modalities.
Conclusions:
- EGFR is a validated therapeutic target in oncology.
- Combination therapies involving EGFR inhibitors show potential for improved patient outcomes.
- Further research into EGFR signaling pathways may reveal novel therapeutic strategies.